Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound preparation method

A compound and organic solvent technology, applied in the field of preparation of boric acid derivatives of pharmaceutical intermediates, can solve problems such as yield decline, difficulty in separation and purification of compound 3, consumption of raw materials by by-products, etc., and achieve the effect of mild reaction conditions

Pending Publication Date: 2019-05-14
SUZHOU PENGXU PHARM TECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] On the one hand, the production of by-products will consume raw materials, resulting in a decrease in the yield of the reaction itself; on the other hand, the existence of too many by-products makes it difficult to separate and purify compound 3, which needs to be purified by using a silica gel column. The yield reported in the literature is separated by silica gel column
In this case, the crystallization purification commonly used in industrial production causes a large amount of product loss, and the yield drops significantly.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation method
  • Compound preparation method
  • Compound preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034]

[0035] Add 2.0 g of p-bromobenzoic acid (compound 1) and 1.11 g of triethylamine into the reaction flask, add 16 mL of dioxane, add 1.25 g of methanesulfonyl chloride dropwise to the system, raise the temperature to 40 °C and stir for 2 h, Add 1.35 g 4-dimethylaminopyridine and 1.41 g o-aminopyridine to the system, add the system and react at 60 °C for 3 h, quench the reaction with 20 mL of water, extract twice with 20 mL of ethyl acetate, combine the organic phases, The solvent was spin-dried and purified by n-heptane / ethyl acetate column chromatography to obtain the product with a yield of 69%.

[0036] The NMR data of compound 3 are as follows:

[0037] 1H NMR (400 MHz, DMSO) δ 10.90 (s, 1H), 8.40 (dd, J = 4.8, 1.1 Hz, 1H),8.18 (d, J = 8.4 Hz, 1H), 8.03 – 7.93 (m, 2H), 7.91 – 7.81 (m, 1H), 7.77 –7.67 (m, 2H), 7.26 – 7.11 (m, 1H).

Embodiment 2

[0039]

[0040] Add 20.0 g of p-bromobenzoic acid (compound 1), 19.34 g of N,N-carbonyldiimidazole into the reaction flask, add 200 mL of toluene, and stir the system at 60 °C for 2 h. 14.04 g o-aminopyridine was added, and the system was reacted at 100 °C for 4 h after the addition was completed. Wash once with saturated sodium carbonate, twice with purified water, once with saturated brine, and concentrate the organic phase to 100 mL, cool to 0-5 °C and stir for 1 h, filter with suction, and dry to obtain the product as a white solid. Yield 84%.

Embodiment 3

[0042]

[0043] Add 10 mL of 2 mol / L tetrahydrofuran solution of isopropylmagnesium chloride into the reaction flask, add 20 mL of tetrahydrofuran, cool the system to -20~-30 °C, add dropwise 16.4 mL of 2.5 mol / L n-butyllithium n-hexane solution, stirred for 10 min. Control the internal temperature at -20~-30 °C, add 35 mL of compound 3 in tetrahydrofuran dropwise, and stir for 20 min. Control the internal temperature at -20~-30 °C, add 3.75 g of trimethyl borate dropwise, maintain the system at -20~-30 °C for 16 h, pour 50 mL of saturated ammonium chloride to quench, and extract with 100 mL of ethyl acetate Three times, the organic phases were combined, the solvent was spin-dried, and purified by dichloromethane / methanol column chromatography to obtain the product with a yield of 45.8%.

[0044] The NMR data of compound 4 are as follows:

[0045] 1 H NMR (400 MHz, DMSO) δ 10.75 (s, 1H), 8.52 – 8.36 (m, 1H), 8.35 – 8.17(m, 2H), 8.11 – 7.79 (m, 5H), 7.24 – 7.12 (m, 1H )....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of a boric acid derivative as a pharmaceutical intermediate. The invention provides a new synthesis scheme of a boric acid compound. The technical schemehas clean reaction and high yield, and a target product with high yield and high quality can be obtained through a simple crystallization scheme.

Description

technical field [0001] The invention relates to a preparation method of a pharmaceutical intermediate boric acid derivative. Background technique [0002] Acalabrutinib (ACP-196, trade name Calquence) is a second-generation covalent inhibitor of Bruton's tyrosine kinase (BTK) developed by AstraZeneca Pharmaceuticals, which is potent and highly selective. Acalabrutinib can promote a sustained high response rate in patients with chronic lymphocytic leukemia (CLL). By blocking BTK, it can inhibit the growth signal of CLL cells until it promotes the death of cancer cells. It has high specificity for its target. As a new generation of therapeutic drugs, Acalabrutinib is a more selective irreversible BTK inhibitor, which will not destroy other molecular channels important to platelet and immune function, and can better improve the safety and effectiveness of the first generation of BTK inhibitors. [0003] Because of its unique efficacy, Acalabrutinib has been approved by the U.S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07F5/02C07D213/75
Inventor 李丕旭王鹏谷向永葛亚东
Owner SUZHOU PENGXU PHARM TECH CO LTD